News

Access and download our newsletters from the Newsletter Archive

 
 

As well as keeping you up to date with the latest developments within the life sciences sector, Bionow members can also post updates to the Bionow News page to promote themselves to over 300 Bionow member organisations and the UK Life Sciences sector.

Whether currently a member or not, keep up to date with all the latest news and events by registering to receive the Bionow newsletter.

The first ever Neuroscience conference, hosted in Sheffield, proved to be a great success with 115 delegates and eight exhibitors collaborating and exploring the current challenges and oppor...

A team of vision researchers from the University of Liverpool have received £2.1m to develop a contact lens that can repair eye damage.

Blueberry Therapeutics Limited (“Blueberry” or “the Company”), a pharmaceutical company focused on developing innovative, topical nanomedicines to treat dermatological conditions, an...

Iksuda Therapeutics announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2

Study confirms ALZmetrixTM whole blood test can detect people at high risk of developing full Alzheimer’s Disease

Pencil Biosciences is developing a fully synthetic gene modulation and editing platform that will have impact across a wide range of applications, including new therapeutic options for patie...

University of Liverpool researchers have secured £2.66m Medical Research Council funding to clinically test a novel immunotherapeutic strategy for non-small cell lung cancer – one of the ...

MedTech company PolyPhotonix has had its innovative diabetes sleep mask adopted in the NHS for the first time.

The report was produced by a working party chaired by a University of Liverpool academic, Professor Sir Munir Pirmohamed

A new Liverpool led study, published in Gut, has identified how immune cells in the body can promote the regrowth of cancer cells after chemotherapy withdrawal. These findings will help impr...

Researchers in Liverpool have begun recruiting patients to a ‘first-in-human’ clinical trial of personalised ‘vaccines’ that aim to reduce the risk of head and neck cancers – which...

Infex Therapeutics has awarded a £1m contract to Lonza to help progress its RESP-X program, a novel therapy which targets serious recurrent respiratory infections in patients with damaged l...

Sign up to our Newsletter

Subscribe

* indicates required

Our Valued Sponsors & Partners